Hydroxy-Chloroquine: Chemoprophylaxis of Malaria and not a Silver Bullet versus COVID-19
Introduction: The world has been facing the pandemic COVID-19. This article highlights the importance of Hydroxychloroquine (HCQ) and Chloroquine (CQ) in the chemoprophylaxis of malaria during the pandemic COVID-19.
Objective: To derive logical conclusion about the indicated use of HCQ/CQ in malaria during the pandemic COVID-19.
Methods: Relevant research articles were retrieved. The online reports, research articles from google, google scholar and PubMed databases were searched and analyzed.
Results: HCQ and CQ are indicated for Malaria and its prophylaxis. The drugs are not silver bullets versus the COVID-19. The available clinical data till the end of July 2020 can be sufficient for the health authorities of various countries to stop using HCQ/CQ to treat COVID-19 patients. The drugs are indicated for malaria instead. Malaria, a potentially deadly parasitic disease in the poorest countries which cannot even afford its preventive measures with HCQ/CQ and other drugs. Misuse of available drugs of Malaria can worsen the disease in the Africa and some Asian countries. The World Health Organization has recommended continuing chemo-prophylactic efforts for malaria during the COVID-19 crisis. Malaria and COVID-19 have certain common symptoms such as fever, headache and body pain which doubles the risk through misleading diagnosis by considering COVID-19 patients as malaria patients and vice versa. WHO has recommended the mass distribution of antimalarial drugs for these counties, so that malaria could not make COVID-19 more deadly.
Conclusion: Use of CQ/HCQ may be continued for the chemoprophylaxis of Malaria during the pandemic COVID-19 and the drugs may not be considered as Silver bullet for COVID-19. Directions of FDA and WHO may be complied regarding use of CQ/HCQ.
Copyright (c) 2020 RADS Journal of Pharmacy and Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting a manuscript to a journal implies that the work has not previously been published in any other journal, printed or online (save as an abstract or an academic thesis), and that it is not currently being considered for publication elsewhere.